Infosys Stock (INFY): Guidance Cut, 52-Week Low — Falling Knife or a 5% Dividend Bargain?

Infosys Limited (INFY) Q1 FY2027 — Infosys (INFY), India's ~$43B #2 IT-services giant, reported Q1 FY2027 (quarter ended June 30) on July 23 — and the NYSE ADR sits at a fresh 52-week low near $10.60, down ~65% from a $30 high last December. The headline looked strong: revenue ₹48,211 cr (~$5.08B) +14% YoY and net profit ₹7,769 cr (~$805M) +12.2%, with operating margin a resilient 21.1%. But in the currency the ADR actually earns — USD, constant-currency — revenue grew just 2.4%, profit fell 8.6% QoQ, and management CUT the top end of FY27 revenue guidance to 1.5–3.0% cc (from 1.5–3.5%) as discretionary spend stays subdued. The offsets: $3.6B in large-deal TCV (61% net new), AI-led revenue already 8.2%, a net-cash balance sheet, ~33% ROE, ~$3.7B FCF (~9% yield) and a ~5% dividend. The debate is whether generative AI deflates the labor-arbitrage model — or just makes it more productive. Our owner-earnings DCF centers near $14.50 vs the ~$10.60 price. Infosys (INFY) is India's second-largest IT-services company — a ~$43B global outsourcer in Bengaluru that writes software, runs systems and now sells AI (via its Topaz platform) to the world's biggest banks, retailers and drugmakers, using ~328,000 mostly-India-based engineers. It trades in New York as a 1:1 ADR but reports in rupees. On July 23 it posted a Q1 FY2027 that split down the middle: revenue ₹48,211 cr (~$5.08B) up 14% and net profit ₹7,769 cr (~$805M) up 12.2% in rupees — yet only +2.4% revenue growth in constant-currency USD, with profit down 8.6% sequentially and EPS ~$0.20/ADR landing in line to soft. The stock, already down ~65% from a December high near $30, fell to a fresh 52-week low near $10.60 — because management trimmed the upper end of FY27 revenue guidance to 1.5–3.0% constant currency (from 1.5–3.5%), citing still-subdued discretionary spending. Two under-covered wrinkles drive the story. First, the rupee: it has weakened ~12% vs the dollar, which inflates the rupee headline and helps margins (costs are in rupees) but erodes what a USD ADR holder compounds — so the honest growth rate is low-single-digit, not 14%. Second, the AI question: AI-led work is already 8.2% of revenue and headcount is flat (328,062, −532 QoQ), which looks more like productivity than a pricing collapse — but if GenAI deflates deal sizes and revenue-per-employee, this labor-arbitrage model is structurally threatened. Against that, the fortress: ~$3.7B free cash flow (~9% yield), ~33% ROE, net cash ~$2.8B, a resilient 21.1% operating margin (guide held at 20–22%), $3.6B in large deals (61% net new), and a ~5% dividend plus buybacks. Our owner-earnings DCF (base ~$3.7B FCF; a 'slow' +2%/yr path and an 'AI-dividend' +6%/yr path; 9–11% discount; ADD ~$2.8B net cash; ÷~4.06B shares) centers near $14.50 vs ~$10.60 — roughly 37% upside, with even the slow case at an 11% discount landing at/above the price. Our call: BUY, 4/5 — a valuation call, not a growth call. The Street is a fence-sitting Hold (15B/21H/4S, ~$13 target, +23%); we differ, more bullish, because the crash appears to have priced in near-zero growth on a debt-free cash machine. The one risk to respect is a structural AI reset. Not financial advice. THE CALL: BUY (4/5, A NET-CASH CASH MACHINE THE MARKET OVERSHOT — SLOW GROWTH AND A REAL AI-DEFLATION RISK, BUT ~37% UPSIDE TO FAIR VALUE WITH A ~5% DIVIDEND TO WAIT AND EVEN THE BEAR CASE AT/ABOVE THE PRICE) — base-case value ~$14.50 vs ~$10.60 today. KEY METRICS: - Revenue ₹48,211 cr (~$5.08B), +14% YoY in INR but only +2.4% YoY in constant-currency USD - Net profit ₹7,769 cr (~$805M), +12.2% YoY but −8.6% QoQ; EPS ~$0.20/ADR, in line to soft vs est. - Operating margin 21.1% (resilient); FY27 margin guide reaffirmed at 20–22% - FY27 revenue-growth guidance CUT: upper end trimmed to 1.5–3.0% cc (from 1.5–3.5%), discretionary spend subdued - Large-deal TCV $3.6B, 61% net new — the order book that refills a slow year - AI-led revenue already 8.2% (Topaz); headcount flat at 328,062 (−532 QoQ), attrition ~13% - Geography (cc): North America +3.2%, Europe +2.8%; led by financial services + life sciences - Free cash flow ~$3.7B FY26 (~9% FCF yield); ROE ~33%; net cash ~$2.8B, near debt-free - Capital return: ~$0.52/ADR dividend (~5% yield at $10.60) plus buybacks - ADR 1:1; reports in INR, trades in USD; FX ~₹96.6/USD; rupee ~−12% YoY drags USD returns; ~4.06B shares - Our owner-earnings DCF fair value ~$14.50 vs ~$10.60 ADR — BUY 4/5, ~37% upside, bear case ~$11 - Street consensus Hold (15B/21H/4S, 40 analysts), ~$13 avg target (+23%) — we're more bullish What to watch: evidence the AI dividend is real rather than deflationary — constant-currency growth re-accelerating back toward mid-single-digits, the $3.6B large-deal book converting to revenue, headcount stabilizing while the 20–22% margin holds — would justify a higher-conviction upgrade; the risks to respect are proof of AI deflation (shrinking deal sizes, falling revenue-per-employee, client price concessions), continued rupee weakness eroding USD/ADR returns, and further guidance cuts, so watch constant-currency growth and pricing every quarter Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.